Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Randomized Experiments01:13

Randomized Experiments

7.0K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
7.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
Clinical Trials01:16

Clinical Trials

6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Hazard Ratio01:12

Hazard Ratio

137
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
137

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

NPJ breast cancer·2026
Same author

Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

The oncologist·2026
Same author

Immunohistochemical characterization of nerve fibers supplying canine elbow joint capsule.

BMC veterinary research·2026
Same author

Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

JAMA oncology·2025
Same author

Clarifying End Point Definitions, Missingness, and Covariate Balance in the International TNT Study-Reply.

JAMA oncology·2025
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
查看所有相关文章

相关实验视频

Updated: Jul 12, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

在随机临床试验中的最小化.

Elisabeth Coart1, Perrine Bamps1, Emmanuel Quinaux1

  • 1IDDI, Louvain-la-Neuve, Belgium.

Statistics in medicine
|October 23, 2023
PubMed
概括
此摘要是机器生成的。

在临床试验中,最小化,一种共变量适应程序,与完全随机或分层封锁设计相比,提高了治疗组平衡. 这种方法对于具有多个预后因素或中心的复杂试验尤其有益.

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

574

相关实验视频

Last Updated: Jul 12, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

574

科学领域:

  • 临床试验设计和方法论
  • 生物统计学 生物统计学
  • 医学研究 医学研究

背景情况:

  • 随机试验通过随机分配确保治疗组的可比性,控制混因素.
  • 尽管随机分配,预后因素的不平衡可能会发生,可能会导致结果偏差.
  • 试验者,监管机构和利益相关者更喜欢在治疗组之间平衡预后因素.

研究的目的:

  • 为了比较最小化,共变量适应程序的性能,与完全随机分配和分层封锁设计进行比较.
  • 根据运营特点,可预测性和实现的平衡来评估这些分配程序.
  • 确定在临床试验中实现最小化的最佳场景.

主要方法:

  • 将最小化与完全随机分配和分层封锁设计进行比较.
  • 利用来自两个临床试验 (卵巢癌,与年龄相关的黄斑变性) 的个体患者数据.
  • 分析运行特征使用异常和随机化测试,评估可预测性,并测量实现的平衡.
  • 研究者在50个实际试验中使用最小化实现了平衡.

主要成果:

  • 与完全随机和分层封锁设计相比,最小化证明了预后因素的优越平衡.
  • 像最小化这样的共变量适应程序可以更好地控制基线不平衡.
  • 在具有众多预后因素,多个中心或适度样本大小的试验中,最小化显示了特定的优势.

结论:

  • 最小化是一种有效的共变量适应程序,用于在随机试验中实现均衡的治疗组.
  • 它在复杂的试验环境中特别有价值,提高了治疗效果估计的可靠性.
  • 该研究强调了最小化对于改善临床试验设计和执行的有用性.